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Abstract
Glutathione (GSH) is implicated in drug resistance mechanisms of several cancers and is a key regulator of cell death
pathways within cells. We studied Ewing’s sarcoma family of tumours (ESFT) cell lines and three mechanistically distinct
anticancer agents (fenretinide, doxorubicin, and vincristine) to investigate whether the GSH antioxidant system is involved
in the reduced sensitivity to these chemotherapeutic agents in hypoxia. Cell viability and death were assessed by the trypan
blue exclusion assay and annexin V-PI staining, respectively. Hypoxia significantly decreased the sensitivity of all ESFT cell
lines to fenretinide-induced death, whereas the effect of doxorubicin or vincristine was marginal and cell-line-specific. The
response of the GSH antioxidant system in ESFT cell lines to hypoxia was variable and also cell-line-specific, although the
level of GSH appeared to be most dependent on de novo biosynthesis rather than recycling. RNAi-mediated knockdown of
key GSH regulatory enzymes c-glutamylcysteine synthetase or glutathione disulfide reductase partially reversed the
hypoxia-induced resistance to fenretinide, and increasing GSH levels using N-acetylcysteine augmented the hypoxia-
induced resistance in a cell line-specific manner. These observations are consistent with the conclusion that the role of the
GSH antioxidant system in modulating the sensitivity of ESFT cells to fenretinide is heterogeneous depending on
environment and cell type. This is likely to limit the value of targeting GSH as a therapeutic strategy to overcome hypoxia-
induced drug resistance in ESFT. Whether targeting the GSH antioxidant system in conjunction with other therapeutics may
benefit some patients with ESFT remains to be seen.
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Introduction
Glutathione (c-glutamylcysteinylglycine, GSH) is the most
abundant non-protein thiol in mammalian cells that functions
both as a homeostatic redox buffer and in cellular defense against
free radicals and reactive electrophiles [1,2]. In cancer cells, GSH
has a dual role both in preventing the initiation of cancer and
promoting the progression of disease through GSH-dependent
drug resistance mechanisms [2,3,4]. Consequently, anticancer
strategies targeting the GSH redox system such as redox chemotherapy
have been developed to modulate the intracellular redox environ-
ment with the expectation this would sensitize cancer cells to
therapy [5] leading to improved therapeutic response and outcome.
Although redox chemotherapy is an emerging anticancer
strategy, it has not been as successful in the clinic as preclinical
studies indicated it might [6,7]. We propose that this may reflect
the presence of hypoxic regions in some tumours that confer
resistance to apoptosis and increase the metastatic potential of
malignant cells as previously reported [8,9]. Hypoxia-induced
drug resistance mechanisms have been widely described
[10,11,12], but the molecular mechanisms are not fully resolved.
In this study we have hypothesised that hypoxia may cause up-
regulation of the GSH antioxidant system in ESFT thereby
attenuating the efficacy of some therapeutics.
Three key enzymes are involved in the regulation of cellular
GSH at the level of biosynthesis (c-glutamylcysteine synthetase,
GCS), regeneration/recycling (glutathione disulfide reductase,
GRD) and breakdown (c-glutamyltranspeptidase, GGT). GCS
is the initiating and rate-limiting enzyme in the biosynthesis of
GSH within cells, whereas GRD and GGT are involved in
the regeneration and breakdown respectively of oxidized GSH
(glutathione disulfide, GSSG). GCS is the target enzyme for inhi-
bition by the GSH-depleting agent L-buthionine S, R-sulfoximine
(BSO) [13] which has been exploited to sensitize some cancer cells to
cytotoxic drugs such as melphalan and cisplatin [14,15]. However
GGT might also be a valuable therapeutic target because it is up-
regulated in many aggressive cancers where it is important in the
maintenance of cellular GSH redox homeostasis [16].
Ewing’s sarcoma is the second most common bone malignancy
found in children and young adults [17], and belongs to the
Ewing’s sarcoma family of tumours (ESFT). ESFT are char-
acterised by non-random gene rearrangements between the EWS
gene on chromosome 22q12 and an ETS gene family member; the
t(11;22)(q24;q12) chromosome rearrangement that produces the
chimeric EWS/Fli1 fusion gene is the most frequently described.
These pathognomonic gene fusions are major drivers of the
development and maintenance of the ESFT malignant phenotype
[17,18]. Current treatment for patients with metastatic ESFT
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apy, incorporating doxorubicin, vincristine, cyclophosphamide,
and etoposide [19]. Despite this intensive treatment regime, the 5
year survival rate for patients with metastatic disease at diagnosis is
less than 25% [20], prompting the need for new treatment
approaches for this cancer. Fenretinide (N-(4-hydroxyphenyl)-
retinamide) is a synthetic retinoic acid derivative that has
documented cytotoxicity in a wide variety of malignant cell types
[21,22,23], including ESFT [10,24,25]. Fenretinide induces cell
death in malignant cells through overproduction of ROS that is
thought to activate the intrinsic cell death cascade [22,24]. This
mechanism of action and minimal toxicity in both adults [26,27]
and children [28,29] makes fenretinide an attractive candidate for
the potential treatment of ESFT.
Previous studies from our laboratory have demonstrated that
fenretinide kills ESFT cells in vitro at concentrations achievable in
vivo [24,25]. Furthermore we have identified the cellular
antioxidant GSH as a determinant of the sensitivity of ESFT cells
to fenretinide in normoxia [25]. Whether GSH plays a similar role
in hypoxia-induced drug resistance was the major question for this
study. We therefore investigated the effect of hypoxia on GSH and
its regulatory enzymes and the response of ESFT cells to selected
therapeutics including fenretinide in normoxia and hypoxia. The
results presented here demonstrate that the involvement of GSH
in hypoxia-induced drug resistance in ESFT is cell line-specific,
and might therefore be tumour-specific. These observations
suggest that optimal patient benefit from redox-based therapies
targeting the GSH antioxidant system may depend on patient-
specific tumour characteristics.
Results
ESFT cells are less sensitive to selected chemotherapeutic
agents in hypoxia
The overall aim of these experiments was to determine whether
the culture environment (normoxia or hypoxia) influenced the
effect of fenretinide, doxorubicin, and vincristine on ESFT viable
cell number. Stabilization of GLUT1 protein confirmed the
hypoxic culture conditions in these experiments (Supporting
Information S1). All five ESFT cell lines were statistically
significantly less sensitive to fenretinide in hypoxia compared to
normoxia (Table 1). In contrast, only one of the five cell lines (TC-
32) showed decreased sensitivity to doxorubicin, and 3 (TC-32,
RDES and SKES-1) out of 5 showed decreased sensitivity to
vincristine in hypoxia. The effect of hypoxia on the IC-50 values
for doxorubicin and vincristine was marginal (p#0.05) compared
to its effect on response to fenretinide (Table 1). These results
suggest that hypoxia-mediated resistance of ESFT cells to
chemotherapeutic agents could be more relevant when these
agents initiate cell death through production of ROS as is the case
with fenretinide.
Fenretinide-dependent decrease in viable cell number is
effected through induction of apoptosis, which is
decreased by hypoxia
Having demonstrated that the cytotoxicity of fenretinide on
ESFT cells was reduced by hypoxia, we went on to investigate
whether this reflected hypoxia-induced changes in proliferation or
apoptosis. Previous studies have suggested in some cell types that
the effect of fenretinide may in part be due to fenretinide-induced
decrease in proliferation [30]. However our results showed that
proliferation of all 5 ESFT cell lines was unaffected by either
hypoxia (Figure 1) or fenretinide treatment (Table 2). There was a
significant reduction in the level of apoptosis in ESFT cells
incubated with fenretinide in hypoxia (Table 2 and Supporting
Information S1), demonstrating that the decrease in fenretinide-
induced cell number in hypoxia reflected a decrease in apoptosis.
Hence from these results we can conclude that fenretinide
decreased ESFT viable cell number through induction of
apoptosis, which is reduced by hypoxia. The effects of doxorubicin
and vincristine on proliferation were cell line specific, in the
majority of cell lines proliferation was unchanged (Supporting
Information S1). The effect of hypoxia on the induction of
apoptosis by doxorubicin or vincristine was also heterogeneous
(Supporting Information S1).
Hypoxia does not alter fenretinide-induced ROS in ESFT
cells
Previous studies have shown that fenretinide-induced cell death
in ESFT cells is dependent on increased level of ROS in normoxia
[24]. We therefore selected two cell lines, RDES and SKES-1, to
establish if the decrease in apoptosis of ESFT cells in hypoxia was
due to alteration in increased level of ROS. Cells cultured in
hypoxia for 12 hours in the absence of fenretinide had a significant
increase in basal ROS levels compared to those cultured in
normoxia (Figure 2A & B). However, when these cells were treated
with 3 mM fenretinide for 30 min–2 hrs (Figure 2C and 2D), a
much larger increase in ROS levels was observed but there was no
significant difference in the magnitude of ROS increase between
cells incubated with fenretinide in hypoxia compared to normoxia.
Table 1. The IC-50 values
a for chemotherapeutic agents in
ESFT cell lines incubated with indicated agents for 48 hours in
normoxia and hypoxia.
Fenretinide (mM)
Cell Line Normoxia Hypoxia P-value
A673 0.42 (0.25–0.59) 3.97 (2.50–5.44) ,0.001
RDES 0.59 (0.24–0.84) 1.69 (1.39–1.99) ,0.01
SKES-1 0.81 (0.33–1.29) 12.6 (10.6–14.9) ,0.001
TC-32 0.75 (0.44–1.06) 7.22 (4.94–9.50) ,0.001
TTC-466 0.25 (0.11–0.39) 1.18 (0.40–1.96) ,0.05
Doxorubicin (nM)
Cell Line Normoxia Hypoxia P-value
A673 22.6 (18.0–30.0) 34.6 (26.8–49.9) NS
RDES 23.1 (19.4–29.0) 15.9 (13.5–18.9) NS
SKES-1 12.6 (10.5–14.9) 12.6 (10.6–14.9) NS
TC-32 4.3 (3.6–5.0) 6.1 (5.3–7.2) ,0.05
TTC-466 24.7 (20.8–31.2) 17.3 (15.2–19.8) NS
Vincristine (nM)
Cell Line Normoxia Hypoxia P-value
A673 3.2 (2.7–3.7) 4.0 (3.4–4.7) NS
RDES 4.6 (4.2–5.1) 5.6 (5.1–6.3) ,0.05
SKES-1 3.7 (3.2–4.1) 4.7 (4.1–5.5) ,0.05
TC-32 6.0 (5.2–6.8) 9.0 (8.0–10.3) ,0.05
TTC-466 3.1 (2.7–3.5) 5.2 (4.6–6.1) NS
aIC-50 values represent the drug concentration that reduced viable cell number
by 50% as assessed by the trypan blue exclusion assay. Values given are IC-50
value (lower-upper 95% CI) for six replicates from 2 independent experiments.
NS: Difference not statistically significant (p.0.05).
doi:10.1371/journal.pone.0028558.t001
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of fenretinide to induce ROS, and suggest that ROS may not be a
critical regulator of the death cascade in these ESFT cells.
The effects of hypoxia on GSH levels and GSH-regulatory
enzymes were cell-line-specific
Since GSH is the major intracellular redox buffer that we have
previously shown modulates the sensitivity of ESFT cells to
fenretinide in normoxia [25], we investigated the hypothesis that
GSH and its regulatory enzymes may be responsible for the
reduced sensitivity of ESFT cells to fenretinide in hypoxia. In
order to investigate the putative role of GSH in hypoxia-induced
resistance mechanisms while minimizing the influence of different
ESFT genotypes, we selected two cells lines (RDES and SKES-1)
with the same EWS/Fli1 fusion type for further study; both cell
lines contain the EWS/Fli1 type II fusion and express p53 and
Figure 1. The effect of hypoxia on proliferation of ESFT cells. Proliferation was measured as the decrease in fluorescence of the plasma
membrane-labelling dye CellVue
TM Claret (see text for details). The graphs are semi-log plots of log10 (CVC fluorescence) vs. time, and differences
between slopes were compared by linear regression analysis. Values represent the mean 6 SEM of n=6 determinations. Open circles=normoxia,
closed circles=hypoxia.
doi:10.1371/journal.pone.0028558.g001
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Supporting Information S1.
GSH levels. The effect of hypoxia on GSH levels in ESFT
cells was cell-line-specific (Figure 3). In RDES cells GSH levels
decreased with time between 0 and 48 hours in both normoxia
and hypoxia; however GSH levels were significantly decreased in
hypoxia compared to levels in normoxia at 16 and 48 hours
(Figure 3, p,0.01). In SKES-1 cells, GSH levels remained
constant over 48 hours in normoxia but were significantly
increased in hypoxia compared to levels in normoxia between 2
and 24 hours (Figure 3, p,0.001).
Glutathione Reductase (GRD). Hypoxia had no significant
effect on GRD activity in RDES or SKES-1 cells (Figure 3),
possibly suggesting that the capacity of ESFT cells to regenerate
GSH was not affected by hypoxia.
c-Glutamylcysteine synthetase (GCS). GCS enzymatic
activity decreased with time in both RDES and SKES-1 cells
maintained in normoxia and hypoxia (Figure 3). However, for
both cell lines GCS activity was significantly higher in hypoxia
compared to normoxia at all time points from 4–48 hours
(p,0.001). The higher GCS activity in hypoxia is consistent
with the hypothesis that hypoxia increases the synthesis of GSH
which potentially contributes to the decreased sensitivity of ESFT
cells to ROS-inducing agents in this environment.
c-Glutamyl transferase (GGT). The enzymatic activity of
GGT remained constant at all time points for both RDES and
SKES-1 cells but was significantly decreased in normoxia for
SKES-1 cells from 16 to 48 hours (Figure 3, p,0.001). This
suggests that in some cell types breakdown of GSH may be
reduced in hypoxia, and could contribute to the decreased
sensitivity to some chemotherapeutics in such environments.
GSH levels are linearly correlated with enzymatic activity
of its regulatory enzymes
In order to establish the wider putative role of GSH in ESFT
cells we investigated the relationship between the activity of GSH
regulatory enzymes and cellular GSH levels in the absence of
chemotherapeutic drugs in normoxia across a panel of 5 ESFT cell
lines. Pearson correlation was used to test the statistical
significance of these relationships. A strong positive correlation
between GRD and GCS activity (Figure 4A, r=0.834) and
between the activities of these two enzymes and levels of GSH
(Figure 4D–E, r=0.648 and r=0.949, respectively) was observed.
Weak to moderate negative correlations between GGT activity
and GCS activity (Figure 4B: r=20. 633), GRD activity
(Figure 4C: r=20. 208), and GSH levels (Figure 4F:
r=20.712) in ESFT cells were also observed. These results
suggest that biosynthesis and regeneration might be the two
reactions that are most critical for maintenance of intracellular
GSH levels in ESFT.
Modulation of intracellular GSH levels and the response
of ESFT cells to fenretinide
Whether GSH plays a role in modulating the sensitivity of
ESFT cells to fenretinide in normoxia and hypoxia was
investigated by (i) depleting intracellular GSH levels using targeted
siRNA-mediated knockdown of GCS and GRD, and (ii) increasing
intracellular levels of GSH by incubating cells with N-acetylcys-
teine (NAC), and then testing the sensitivity of these cells to
fenretinide when maintained under normoxia or hypoxia.
(i) Effect of siRNA-dependent decrease in GSH levels on
response of RDES and SKES-1 cells to fenretinide in
normoxia and hypoxia. Having identified GRD and GCS as
the two enzymes that are important for regulating intracellular
GSH levels in ESFT, we investigated whether siRNA-mediated
knockdown of these two enzymes might sensitize ESFT cells to
fenretinide. The magnitude of siRNA-mediated knockdown of
GRD and GCS catalytic subunit on protein levels, enzymatic
activity, and GSH levels are shown in Figure 5A, B, & C for
RDES and Figure 5F, G, H, & J for SKES-1 cells. Treating
siRNA-loaded RDES cells with fenretinide significantly increased
the sensitivity of these cells to fenretinide in both normoxia and
hypoxia (Figures 5D & 5E, p,0.001); the combined knockdown of
GRD and GCS catalytic subunit using siRNA achieved a greater
effect than either siRNA alone (p,0.0001). In hypoxia, siRNA-
mediated knockdown of either GRD or GCS alone failed to
sensitize SKES-1 cells to fenretinide (Figure 5J), however double
knockdown of the two enzymes together enhanced fenretinide
cytotoxicity (Figure 5J, p,0.0001). These results are consistent
with the regulatory role of these enzymes on GSH levels establish
earlier, and suggest that targeting multiple GSH regulatory
enzymes may be needed to overcome hypoxia-induced GSH-
dependent drug resistance of some ESFT cells. The results of
siRNA-mediated knockdown of the GCS catalytic subunit in the
two ESFT cell lines are thus consistent with our previous
observations that showed increased sensitivity to fenretinide
following inhibition of GCS enzymatic activity by BSO [25].
(ii) Effect of NAC-dependent increase in GSH levels on
response of RDES and SKES-1 cells to fenretinide in
normoxia and hypoxia. We hypothesized that if GSH was a
critical factor in reducing the sensitivity of ESFT to fenretinide in
hypoxia, then an increase in intracellular GSH levels should
augment this effect. To test this hypothesis we used NAC to
increase intracellular GSH levels in ESFT cell lines and then tested
their sensitivity to fenretinide in both normoxia and hypoxia.
Treatment of RDES and SKES-1 cells with 5 mM NAC for
Table 2. Effects of fenretinide on proliferation and apoptosis
levels of ESFT cells in normoxia and hypoxia over 48 hours.
Proliferation (Slope of linear regression curve)
a
Cell Line Normoxia Hypoxia P-value
A673 20.011360.0005 20.011260.0002 0.7264
RDES 20.008560.0003 20.007960.0002 0.0910
SKES-1 20.010160.0005 20.009560.0006 0.5132
TC-32 20.007660.0004 20.007760.0006 0.9159
TTC-466 20.010060.0004 20.010260.0003 0.7187
Apoptosis (% apoptotic cells)
b
Cell Line Normoxia Hypoxia P-value
A673 45.361.3 15.061.0 0.0022*
RDES 72.162.3 26.362.0 0.0022*
SKES-1 57.461.3 24.063.0 0.0022*
TC-32 55.062.3 22.261.7 0.0022*
TTC-466 78.363.4 43.862.4 0.0022*
aThis is the slope of the graph of log CVC fluorescence vs. time. A full
description of the analyses is given in the text.
bApoptosis was assessed by Annexin-V/PI staining, acquired by FACS and
analysed using CellquestPro
TM software. The percentage value shown is the
sum total of cells that stained positive for Annexin-V alone, Annexin-V+PI
together, and PI alone. The data were compared statistically using the non-
parametric Mann-Whitney-Wilcoxon rank sum test. Values shown are mean 6
SEM of n=6 determinations.
*Value in hypoxia is significantly different from normoxia at p value indicated.
doi:10.1371/journal.pone.0028558.t002
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and D). Increasing cellular GSH levels in RDES cells caused the
cells to become more resistant to fenretinide-induced cell death in
normoxia (Figure 6B: IC-50 value NAC treated=1.41 mM
compared to IC-50 value control=0.85 mM, p,0.0001) and
augmented the resistance to fenretinide in hypoxia (Figure 6C: IC-
50 value NAC treated=2.00 mM compared to IC-50
control=1.86 mM, p,0.0091). In SKES-1 cells, the result of
increasing GSH levels on sensitivity to fenretinide was less
dramatic in both normoxia (Figure 6E: IC-50 value NAC
treated=1.77 mM compared to IC-50 value control=1.66 mM,
p,0.07) and hypoxia (Figure 6F: IC-50 value NAC
treated=2.42 mM compared to IC-50 value control=2.31 mM,
p,0.36) compared to changes observed in RDES cells. The
augmentation of RDES resistance to fenretinide in hypoxia after
artificially increasing GSH levels supports the hypothesis that
GSH plays a role in the reduced sensitivity of ESFT cells to
fenretinide in this microenvironment. However, the lack of effect
of increasing GSH on sensitivity of SKES-1 cells to fenretinide in
normoxia or hypoxia demonstrates that the involvement of GSH
in modulating sensitivity of ESFT to fenretinide is heterogeneous,
and strongly suggests the involvement of other factors in hypoxia-
induced drug resistance.
Discussion
Identifying factors that contribute to the reduced sensitivity of
ESFT to therapeutics in low oxygen environments could enable
the design of novel therapies that are more effective in treating
disease. In this study we identified GSH as one factor that may
be important in modulating the response of some ESFT cells
to fenretinide in hypoxia. However the response of the GSH
antioxidant system in the 5 ESFT cell lines to hypoxia was cell-
line-specific and the response of ESFT cell lines to modulation of
intracellular GSH levels was heterogeneous. This is consistent with
our view that the GSH antioxidant system may play a role in
hypoxia-induced drug resistance in some but not all ESFT, and
the proposition that this should be characterised in tumours to
establish which patients might benefit from therapies exploiting
regulators of the GSH antioxidant defence system. Since GSH is
Figure 2. Fenretinide induces ROS production in both normoxia and hypoxia. (A) Representative histograms of the effects of hypoxia and
treatment with fenretinide on ROS production in the RDES cell line. (B) Hypoxia caused a significant increase in basal levels of ROS in both RDES and
SKES-1 cell lines in the absence of fenretinide. (C–D) The magnitudes of ROS increase following treatment of ESFT cells with fenretinide (3 mM) were
similar in normoxia and hypoxia over a period of 30 min–2 hrs. Values are mean 6 SEM of n=3 independent experiments. *Value significantly
different from zero time control at p#0.01.
doi:10.1371/journal.pone.0028558.g002
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peutics, we have taken the view that future combination
treatments exploiting the GSH antioxidant defence system may
potentially improve treatment outcome in selected patients with
ESFT [7].
The regulation of cellular GSH occurs at multiple levels
involving biosynthesis, regeneration, and degradation. Results of
this study show a strong positive correlation between GSH levels
and GCS activity, suggesting that de novo synthesis may be more
important for GSH preservation in ESFT than recycling or
Figure 3. GSH levels and the activity of GSH-regulatory enzymes in RDES and SKES-1 cells. Cells were harvested at the time points
indicated for determination of GSH levels and the activities of GRD, GCS, and GGT1 as described in the text. Each bar represents the mean 6 SEM of
n=6 determinations. Grey bars=normoxia; Black bars=hypoxia. *Hypoxia values significantly different from those in normoxia at p#0.01.
doi:10.1371/journal.pone.0028558.g003
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large catalytic subunit of molecular weight 78 kDa and a smaller
regulatory subunit of 31 kDa. Transcriptional regulation of both
GCS subunits is mediated by the nuclear factor (erythroid-derived
2)-like 2 (Nrf-2) transcription factor, the master switch for cellular
antioxidant defence [31], whereas post-transcriptionally the
activity of the holoenzyme is affected by phosphorylation [32].
Inhibition of GCS enzyme leads to GSH depletion within cells
Figure 4. Pearson correlation modelling of the relationships between GSH and its regulatory enzyme activities in ESFT. The
parameters were measured in ESFT cells cultured under normoxic conditions in the absence of fenretinide. (A–C) Relationships between the
enzymatic activities of GSH regulatory enzymes. (D–F) Correlation between activities of GSH-regulatory enzymes and GSH levels in ESFT cells.
doi:10.1371/journal.pone.0028558.g004
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28558Figure 5. Effects of siRNA-targeted knockdown of GRD and GCS on sensitivity of RDES (A–E) and SKES-1 (F–J) cells to fenretinide.
Western blots (Panels A & F) show decreased GRD and GCS protein levels in RDES and SKES-1 cells electroporated with siRNA. Enzymatic activities of
GRD and GCS were decreased in both RDES (Panel B) and SKES-1 (Panel G) cells following electroporation with siRNA, *p,0.0001. GSH levels were
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GSH levels via induction of GCS [32,33]. There is currently no
information on how GCS activity (hence cellular GSH levels) is
affected or regulated by hypoxia in vitro. Here we report for the
first time that GCS enzymatic activity was increased by hypoxia in
two ESFT cell lines. On the basis of these results we postulate that
the higher GCS activity in hypoxia may indirectly contribute to
reduce sensitivity of ESFT cells to fenretinide by increasing the
GSH antioxidant defence against drug-induced oxidative stress or
dampening of pro-apoptotic stimuli [3]. Therefore in some
tumours targeting GCS may provide an opportunity to increase
sensitivity to fenretinide under hypoxic conditions.
The results in this manuscript on the effects of hypoxia on ROS
production and the sensitivity of ESFT cells to chemotherapeutic
agents are at variance with some of the current literature. In this
study we observed that the level and time course of ROS increase
following treatment of ESFT cells with fenretinide were similar in
hypoxia and normoxia, suggesting the differential response of
ESFT cells to fenretinide in hypoxia and normoxia was not a result
of differences in the levels of ROS produced. This is in contrast to
results reported by Batra et al. [10] who described a decrease in
ROS levels in hypoxia compared to normoxia 6 hours after
treating SK-N-MC cells with fenretinide [10]. We have not
investigated the SK-N-MC cell line and so cannot directly
compare our data with that of Batra et al. [10], however this
discrepancy may reflect differences in methodology and/or timing
of ROS assays. Our own results are consistent with previous
publications demonstrating that ROS production is an early
initiating event in fenretinide-induced death in ESFT [24]. These
discrepancies may also suggest that fenretinide induces cell death
through other non-ROS mechanisms such as ceramide production
[10] or through death receptors [34] that could be cell line-
specific.
In this study we have found a significant reduction in the
sensitivity of all ESFT cells to fenretinide in hypoxia, but the
resistance to doxorubicin and vincristine was marginal and cell-
line-specific. This is in contrast to the findings of Kilic and co-
workers who reported decreased sensitivity of the A673 cell line to
doxorubicin and vincristine in hypoxia [12]. Two possible
explanations for this discrepancy could be differences in culture
conditions between the two studies and/or the methods used to
assess and analyze cell death in drug-treated cells. In this study
ESFT cells were maintained in a hypoxic environment (1% O2,
5% CO2, and 94% N2), whereas in the study from Kilic et al. [12]
experimental conditions were anoxic (5% CO2 and 95% N2),
hence the response of cell lines to drug treatment in these two
environments may differ. Furthermore, different methods to assess
the efficacy of the drugs were used. Kilic et al. [12] used a FACS-
based method to measure DNA fragmentation of PI-stained cell
nuclei [12] whereas we used the trypan blue exclusion assay to
measure viable cell number and the FACS-based Annexin V-PI to
quantify the level of apoptotic cell death. While these three
methods are all useful for assessing cell death in a range of cell lines
and conditions, the assay endpoints are different so consequently
results from one assay may not be directly comparable to those of
another within a given time and experimental design. We have
therefore taken the view that the results obtained with one method
should be validated by at least a second methodological approach
and have utilised the trypan blue exclusion assay and Annexin V-
PI to quantify effects in this study.
The EWS/Fli1 transcription factor plays a major role in
regulating apoptosis in ESFT both in vitro and in vivo [35,36] and
enhances the drug resistant phenotype of ESFT cells in hypoxia in a
HIF-1a-dependent manner [37]. Hence to eliminate the influence
of different EWS/Fli1 fusion types on sensitivity to fenretinide
toxicity in this study we used RDES and SKES-1 cell lines that are
both EWS/Fli1 fusion type II and hemizygous null for p53 to study
the role of GSH in greater detail. Using these two ESFT cell lines
with some common genetic features we observed that the role of
GSH in mediating the resistanceto fenretinide was cell-line-specific.
This implicates the induction of other drug resistance mechanisms
in the response of ESFT to fenretinide. These are most likely HIF-
1a regulated and may involve decreased senescence [38], induction
of an autophagy-dependent pro-survival mechanism [39,40], or
hypoxia-induced modulation of factors involved in the initiation of
cell death such as ceramide [10].
In conclusion, this study demonstrates that the role of GSH in
modulating the sensitivity of ESFT cells to fenretinide is
heterogeneous depending on the environment and cell type.
While manipulation of GSH levels using siRNA-targeted knock-
down of its regulatory enzymes or artificially increasing its
intracellular levels using NAC supplementation partly supports
the hypothesis that GSH could be involved in hypoxia-induced
drug resistance, a major caveat is that its role appears to be cell
line-specific. This is likely to limit the value of targeting GSH alone
as a therapeutic strategy for overcoming hypoxia-induced drug
resistance of ESFT.
Materials and Methods
Chemicals and reagents
Cell culture media: RPMI 1640, DMEM, MEM, and McCoy’s
were purchased from Sigma -Aldrich (UK). Opti-MEMH I
reduced-serum media was procured from Invitrogen (Paisley,
UK). The chemotherapeutic drugs fenretinide, doxorubicin, and
vincristine were also purchased from Sigma-Aldrich (UK) and
dissolved in absolute ethanol (fenretinide) or water. Bovine foetal
calf serum (FCS) was obtained from Seralab (Sussex, United
Kingdom) and stored frozen in single use aliquots at 220uC. The
redox-sensitive dye used for ROS detection, 5-(and 6-)-chloro-
methyl-29-79-dichlorofluorescein diacetate acetyl ester (CM-
H2DCFDA) and the Alexa FluorH 680 secondary antibodies were
purchased from Molecular Probes (Eugene, OR, USA). The
Annexin V-FITC Apoptosis Detection kit for assessing cell death
was purchased from BD Biosciences (UK). The glutathione (GSH)
standards, adenosine-59-triphosphate (ATP), 2,3-naphthalenedi-
carboxaldehyde (NDA), 5-sulfosalicylic acid (SSA), c-glutamyl-p-
nitroanilide (GPNA), p-nitroaniline, L-glutamic acid, L-cysteine,
N-acetylcysteine, L-serine, L-buthionine-S,R-sulfoximine (BSO),
metaphosphoric acid, and the CellVueHClaret kit used for
measuring cell proliferation were procured from Sigma-Aldrich
(UK). The antibodies for GRD (ab16801), GCS (ab40929), and
GLUT1 (ab32551) were purchased from AbcamH (Cambridge,
UK). The GRD activity kit was purchased from Cayman Europe
(Estonia). The pre-designed SilencerH Select siRNAs used for the
knockdown of GCS (s5800) and GRD (s6249), and the scrambled
also significantly decreased in RDES (Panel C) and SKES-1 (Panel H) cells following electroporation with siRNA, *p,0.0001. Sensitivity of ESFT cells to
fenretinide was improved by decreasing GSH levels in both RDES (Panels D & E) and SKES-1 (Panels I & J) cells in normoxia and hypoxia. For panels
D,E,I, and J, white bars=electroporated control; light grey bars=control non-specific siRNA; grey bars=siGRD; dark grey bars=siGCS; Black
bars=siGRD+siGCS (400 nM each), *p#0.01; **p#0.0001.
doi:10.1371/journal.pone.0028558.g005
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(negative control) were purchased from Applied Biosystems (UK).
Cell culture
Five substrate-adherent ESFT cell lines A673, RDES, SKES-1,
TC-32, and TTC-466 were used in this study. The A673, RDES,
and SKES-1 cells were purchased from the American Type
Culture Collection, Manassas, VA. TC-32 and TTC-466 cell lines
were kind gifts from Dr J. Toretsky (Division of Pediatrics,
University of Maryland, Baltimore, MD) and Dr P. Sorenson
(British Columbia Children’s Hospital, Vancouver, British Co-
lumbia, Canada), respectively. Cell line identity was confirmed by
Figure 6. The effect of increasing GSH levels by NAC supplementation on sensitivity of RDES (Panels A–C) and SKES-1 (Panels D–F)
cells to fenretinide. NAC supplementation significantly increased GSH levels in RDES (Panel A) and SKES-1 (Panel D) by between 10 and 50%
compared to un-supplemented controls. The effects of increasing GSH levels in RDES (Panels B–C) and SKES-1 (Panels E–F) cells were cell line-specific.
*Number of viable cells was significantly different between normoxia and hypoxia, specific IC-50 values are reported in the text.
doi:10.1371/journal.pone.0028558.g006
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before and during the course of the study as per ATCC and
European LGC recommendations. In addition, checks on cell line-
specific characteristicss that include G-banding for chromosome
number, RT-qPCR to confirm fusion transcripts, and multiplex
ligation-dependent probe amplification (MLPA) analysis to verify
p16 status of each cell line were done every 6–12 months. All cell
lines were cultured without antibiotics in medium containing 10%
FCS except where indicated. Mycoplasma tests (MycoAlertH
Mycoplasma detection assay, Lonza) were carried out bi-monthly
during the course of the study to ensure cells were free from
contamination in the absence of antibiotics. A673 cells were grown
in DMEM medium, whereas RDES, TC-32, and TTC-466 cells
were grown in RPMI 1640 media; the media for TTC-466 cells
was supplemented with 10% sterile conditioned media. SKES-1
cells were grown in McCoy’s medium containing 15% FCS. All
incubations and cell treatments were carried out in humidified
normoxic incubators (Sanyo Gallenkamp, Loughborough, UK)
containing 5% CO2 and 95% air at 37uC, or hypoxic incubators
containing 1% oxygen, 5% CO2 and 94% nitrogen at 37uC.
Effect of chemotherapeutic drugs on ESFT cell viability
ESFT cells (5610
4 cells/well) were seeded into 24-well Primaria
plates and allowed to adhere overnight in a normoxic incubator.
Cells were then incubated in normoxia or hypoxia and treated
with the following chemotherapeutic drugs: fenretinide (0–15 mM),
doxorubicin (0–50 nM), and vincristine (0–20 nM). Cell viability
was assessed by the trypan blue exclusion assay after 48 hours.
These three drugs were selected based on their distinct
mechanisms of action for inducing cell death. Fenretinide induces
cell death in malignant cells by increasing levels of intracellular
ROS to activate the intrinsic mitochondrial death cascade [41]
whereas doxorubicin and vincristine do so by DNA intercalation
or inhibition of DNA topoisomerase II [42,43], and inhibition of
mitosis by disrupting microtubule formation [44], respectively.
ESFT cell proliferation and apoptosis
Whether hypoxia affected proliferation or apoptosis of ESFT
cells was evaluated using the CellVueH Claret and annexin-V/PI
assays, respectively.
To measure proliferation of cells in normoxia and hypoxia, the
CellVueHClaret assay was utilised according to manufacturer’s
instructions. Briefly, cells were harvested by trypsinization, washed
three times with serum-free media and then resuspended in
staining media (company proprietary) at a density of 2610
7 cells/
ml. An equal volume of 4 mM CellVueH Claret dye (CVC) in
staining media was then added to the cells to give a final
concentration of 2 mM CVC. After mixing, the cells were
incubated for 5 minutes at room temperature and then the
reaction was stopped by addition of an equal volume of serum.
The cells were then washed three times in serum-containing
media, viable cell number counted, and cells seeded into 6-well
plates at a density of 2610
5 cells/well before placing in either
hypoxic or normoxic incubators. After 24, 48, and 72 hours the
cells were harvested by trypsinization for measurement of
fluorescence by FACS analysis (excitation wavelength 655 nm;
emission wavelength 675 nm). The proliferation of cells is directly
proportional to the decrease in mean fluorescence of the CVC dye
with time in live cells.
The effects of chemotherapeutic drugs on cell proliferation were
assessed in similarly designed experiments but the chemothera-
peutic drugs were added 24 hours after the CVC dye and the
fluorescence measured subsequently at 24 and 48 hours. The level
of apoptosis was assessed by staining cells with Annexin V and PI
according to the protocol described in the Annexin V-FITC
Apoptosis Detection kit from BD Biosciences (UK); data
acquisition and analysis was performed using FACS and
CellquestPro
TM software.
Measurement of intracellular ROS levels
The fluorescent dye CM-H2DCFDA was used to assess the levels
of ROS in ESFT cells by FACS analysis as previously described
[25]. For ROS measurements in hypoxic cells, cells were taken out
of the incubator for harvesting under normoxic conditions and
quickly replaced in incubator after labelling with CM-H2DCFDA
dye. After the 15 min incubation period cells were twice washed
with PBS by spinning at 4006g at room temperature and FACS
analysisofthedye-labelled cellswasperformedasquicklyaspossible
within 30 minutes after harvesting.
Western blotting
GRD, GCS, and GLUT1 protein levels were assessed using the
Western blotting method previously described [25]. Primary
antibodies were diluted as recommended by supplier and the
secondary antibodies were diluted 1:5000. Protein bands were
detected using the Odyssey
TM Infrared detection system (Li-COR
Biosciences, Lincoln, NE).
Measurement of GSH levels
ESFT cells (2610
5) were placed into 10 cm
2 dishes and allowed
to adhere overnight under normoxic conditions. Half the dishes
were then placed in a hypoxic incubator and the rest maintained
in normoxia. Cells were harvested after 0, 2, 4, 6, 16, 24, and
48 hours by scraping into ice-cold PBS and centrifugation at 4006
g for 5 minutes, and PBS removed by aspiration. The cell pellets
were immediately homogenized in 500 ml MES buffer and GSH
levels were determined in fresh cell extracts using the enzymatic
recycling method as previously described [25]. The GSH level was
normalized to total cellular protein concentration estimated in
cell extracts using the Bio-Rad DC Protein Assay kit (Bio-Rad,
Herts. UK).
Measurement of GSH regulatory enzyme activities
These experiments were set-up was as described above using
cells that were sub-confluent at the time of harvesting. Cells were
homogenized in 50 mM potassium phosphate (pH 7.5) containing
1 mM EDTA for the GRD assay; 120 mM Tris-glycyglycine
buffer (120 mM Tris, 80 mM glycylglycine, 1% Triton X, 10%
glycerol, pH 8.0) for the GGT assay; and TES/SB buffer (20 mM
Tris, 1 mM EDTA, 250 mM sucrose, 20 mM sodium borate,
2 mM serine) for the GCS assay. Homogenates were centrifuged
at 12 0006g (15 minutes, 4uC) and the supernatants maintained
on ice for determination of enzyme activities. The protein
concentration of cell supernatants was measured using the Bio-
Rad DC Protein Assay kit (Bio-Rad, Herts. UK) and enzyme
activities reported as mUnits/mg of protein, where a unit of
activity is the amount of enzyme required to convert one mmole of
substrate to product per minute at 25uC.
The Glutathione Reductase Assay Kit
TM (Cayman Europe,
Estonia) was used to measure GRD activity in ESFT cell extracts
by determining the rate of NADPH oxidation according to
manufacturer’s instructions. GGT activity was measured accord-
ing to the kinetic procedure [45]; in this method the substrate
analogue GPNA is cleaved by GGT present in cell extracts to form
p-nitroaniline, production of which is determined spectrophoto-
metrically at 405 nm. This GCS assay is an adaptation of the
method previously described [46], in which GCS in cell extracts
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form a highly-fluorescent product that can be measured
fluorimetrically at 520 nm [46].
Electroporation of cells with GRD and GCS siRNA
ESFT cells were electroporated with siRNA targeting either
GRD (siGRD) or GCS (siGCS) to achieve knockdown of these
proteins. The siGCS (s5800) targets the catalytic subunit of the
GCS enzyme for knockdown. Briefly, (2–10)610
5 cells were
suspended in 0.4 ml of culture media in 0.4-cm cuvettes (Bio-Rad).
After addition of siRNA to the cuvette, cells were subjected to an
electrical pulse (Voltage=0.4 kV, Capacitance=500 mF) for 12–
15 ms in a Gene Pulser II instrument (Bio-Rad, UK). Two control
groups consisted of cells electroporated with scrambled non-
specific (negative control) siRNA (Applied Biosystems, UK) and
cells electroporated in the absence of siRNA. After electroporation
cells were seeded into six well plates in normoxia and cells
harvested at 24–72 hours for the preparation of protein extracts
and western blotting (see above) to evaluate the magnitude and
duration of GRD and GCS knockdown. The effect of fenretinide
(0.5–5.0 mM) on viable cell number of cells maintained in the
hypoxic incubator and under normoxia for 48 hours was then
compared; viable cell number was assessed using the typan blue
exlusion assay.
Artificially increasing cellular GSH levels in ESFT cells
Cellular levels of GSH were artificially increased by treating
ESFT cells (2610
5) with a non-toxic concentration of NAC
(5 mM) for 24 hours in 6-well primaria plates. NAC supplemen-
tation increases intracellular GSH levels by providing the essential
amino acid cysteine that is required for GSH biosynthesis [47].
Control cells were treated with vehicle only. After 24-hour, cells
from one plate in each group were harvested as described above to
determine the baseline level of GSH. Media was then aspirated
from the remaining plates and replaced with fresh media
containing fenretinide (0.5–4.0 mM). The fenretinide-treated cells
were then incubated in normoxia or hypoxia for 48 hours after
which viable cell number was analyzed by the trypan blue
exclusion assay.
Statistical analyses
All data were analyzed using GraphPad PrismH statistical
software (GraphPad Software Inc., La Jolla, CA). Only p values
less than 0.05 (p,0.05) were considered statistically significant.
Differences in viable cell number or proliferation of normoxia-
and hypoxia-cultured ESFT cells were tested by linear regression
analysis of the slopes of log-linear plots of the logarithm of viable
cell number or CVC fluorescence (proliferation) against time.
Results from the Annexin V-PI assays to assess cell death after
treatment with chemotherapeutic agents in normoxia and hypoxia
were compared statistically using the non-parametric Mann-
Whitney-Wilcoxon rank sum test. GSH levels and activities of
GRD, GCS, and GGT enzymes between cells grown in normoxia
and hypoxia at each time point were compared statistically using
2-way ANOVA followed by Bonferroni post-hoc tests. The
correlations between GRD, GCS, GGT and GSH levels were
examined using Pearson’s correlation.
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